TMCnet News
Spero Therapeutics to Present Data at IDWeek 2021CAMBRIDGE, Mass., Sept. 16, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced 23 data presentations at the Infectious Disease Society of America (IDSA) IDWeekTM 2021, taking place virtually from September 29 – October 3, 2021. Presentations will showcase in vitro and in vivo studies of Spero’s oral antibiotic investigational candidate tebipenem HBr for the treatment of adults with complicated urinary tract infection (cUTI) and acute pyelonephritis (AP) and highlight additional research on the epidemiology and management of cUTI. Presentations pertaining to tebipenem HBr and the epidemiology and management of cUTI: 1. Title: Tebipenem in vitro activity against a collection of pathogens responsible for urinary tract infections in the US 2. Title: In vitro activity of tebipenem against clinically significant gram-negative bacteria isolated from patients with cancer 3. Title: Development of tebipenem MIC antimicrobial susceptibility test for gram-negative bacteria on MicroScan dried gram-negative MIC panels 4. Title: Pharmacokinetics-pharmacodynamics evaluation of tebipenem pivoxil hydrobromide using the 10-day hollow-fiber in vitro infection model 5. Title: Population pharmacokinetic analyses for tebipenem after the administration of tebipenem pivoxil hydrobromide 6. Title: Oral tebipenem as step-down therapy following intravenous ertapenem in a 7-day hollow-fiber in vitro model 7. Title: Absorption, metabolism, and excretion of [14C]-tebipenem pivoxil hydrobromide (TBP-PI-HBr) following a single oral dose in healthy male subjects 8. Title: Bioequivalence of two formulations of oral tebipenem-pivoxil hydrobromide in healthy subjects 9. Title: Effect of aluminum hydroxide/magnesium hydroxide/simethicoe and omeprazole on the pharmacokinetics of tebipenem pivoxil hydrobromide (TBP-PI-HBr) in healthy adult subjects Date: Wednesday, September 29, 2021 Poster Session: A2. PK/PD Studies Poster Number: 1122 10. Title: In vitro activity of tebipenem and comparators against Enterobacterales collected from patients with bloodstream infections as part of the 2019 global STEWARD surveillance program 11. Title: Molecular epidemiology of Escherichia coli causing urinary tract infections in the United States and in vitro activity of tebipenem, including against strain lineage and resistant subsets (2018-2020) 12. Title: An evaluation of tebipenem in vitro activity against a panel of Pseudomonas aeruginosa isolates with Efflux, AmpC, and OprD Mutations 13. Title: In vitro analysis of AmpC ß-lactamase induction by tebipenem in Enterobacterales and Pseudomonas aeruginosa 14. Title: In vitro activity of tebipenem, an orally available carbapenem agent, against a collection of surveillance Gram-positive clinical isolates 15. Title: In vitro activity of tebipenem against a recent collection of fastidious organisms recovered from respiratory tract infections 16. Title: In vitro activity of tebipenem against relevant clinical isolates in the presence of pulmonary surfactant 17. Title: Medicare spending on urinary tract infections: a retrospective database analysis 18. Title: High prevalence of fluoroquinolone-resistant urinary tract infection among US emergency department patients diagnosed with UTI, 2018-2020 19. Title: Descriptive epidemiology of UTI hospitalizations in the US, 2018 20. Title: Empiric antimicrobial prescribing for urinary tract infections in patients discharged from the emergency department 21. Title: Healthcare resource utilization during hospitalizations with UTI in the US, 2018 22. Title: Descriptive epidemiology of emergency department visits with cUTI in the US, 2012-2018 23. Title: Epidemiology and 12-month antibiotic use in the outpatient setting among adult patients with complicated urinary tract infections: a retrospective database analysis About Spero Therapeutics Spero’s lead product candidate, tebipenem HBr (tebipenem pivoxil hydrobromide; formerly SPR994), is being developed as the first oral carbapenem antibiotic for use in complicated urinary tract infections (cUTI) and acute pyelonephritis (AP). In September 2020, Spero announced positive top-line results from its Phase 3 ADAPT-PO clinical trial of tebipenem HBr in cUTI and AP. Spero is also developing SPR720 as a novel oral therapy product candidate for the treatment of rare, orphan pulmonary disease caused by non-tuberculous mycobacterial (NTM) infections. Spero also has an IV-administered next generation polymyxin product candidate, SPR206, developed from its potentiator platform, which is being developed to treat MDR Gram-negative infections in the hospital setting. For more information, visit https://sperotherapeutics.com. Investor Relations Contact: Media Contact: |